Rectal Cancer Patients clinical trials

Explore recruiting rectal cancer patients clinical trials.

Recruiting rectal cancer patients studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Rectal Cancer Patients trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A PHASE 2A, EXPLORATORY, TWO-PART, OPEN-LABLE TRIAL TO EVALUATE DOSE AND SAFETY OF NANOECHO PARTICLE-1 (FERUMOXTRAN) USING NANOECHO IMAGING DEVICE EXAMINATIONS OF RECTAL LYMPH NODES IN HEALTHY VOLUNTEERS (PART A) AND RECTAL CANCER PATIENTS (PART B).

Sweden

Therapeutic exploratory (Phase II) EU CTIS Study details

NEOadjuvant chemotherapy only compared with standard treatment for Locally Advanced Rectal cancer: a randomized phase II trial

Denmark

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Systemic Neoadjuvant and adjuvant Control by Precision medicine in rectal cancer (SYNCOPE) – approach on high-risk group to reduce metastases

Finland

Therapeutic use (Phase IV) EU CTIS Study details

Neo-adjuvant FOLFOXIRI and chemoradiotherapy for high risk (“ugly”) locally advanced rectal cancer.

Netherlands

Therapeutic exploratory (Phase II) EU CTIS Study details

Adjuvant chemotherapy for prevention of recurrence in patients with detectable ctDNA after surgery in high-riskrectal cancer.

Netherlands

Therapeutic confirmatory (Phase III) EU CTIS Study details

PRODIGE 90 - FFCD 2204 - PREDIR-NEOREC - Neoadjuvant dostarlimab with short course radiotherapy in a watch-and-wait strategy for microsatellite unstable or mismatch repair-deficient locally advanced rectal cancer patients: a randomized phase II trial

France

Therapeutic exploratory (Phase II) EU CTIS Study details

Rectal Cancer Patients trials by city

Rectal Cancer Patients in Toronto Rectal Cancer Patients in Vancouver Rectal Cancer Patients in Montreal Rectal Cancer Patients in Calgary Rectal Cancer Patients in Edmonton Rectal Cancer Patients in Ottawa Rectal Cancer Patients in Winnipeg Rectal Cancer Patients in Quebec City Rectal Cancer Patients in Hamilton Rectal Cancer Patients in Kitchener Rectal Cancer Patients in London Rectal Cancer Patients in Halifax Rectal Cancer Patients in New York Rectal Cancer Patients in Los Angeles Rectal Cancer Patients in Chicago Rectal Cancer Patients in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease